HGH 191AA (somatropin) dosing — how it is framed

Somatropin is recombinant human growth hormone, given subcutaneously. Injected GH clears from circulation within hours, but the biologically meaningful readout is downstream: GH stimulates hepatic production of IGF-1, and serum IGF-1 integrates exposure over a much longer window. That is why clinical dosing is steered by IGF-1 concentrations rather than by trough GH levels, and why a single "how many IU" answer does not exist.

Because somatropin bypasses the pituitary rather than stimulating it, the relationship between amount given and IGF-1 achieved is fairly direct — there is no somatostatin feedback ceiling as there is with a secretagogue. Predictability in that direction is exactly what makes careful titration necessary.

Two structural features of that labeling are worth naming. First, the dose is indication-specific — the label lists separate weekly figures for Prader-Willi syndrome, small for gestational age, Turner syndrome, and idiopathic short stature, and they are not interchangeable. Second, adult dosing has no fixed target at all; it is defined as a starting point plus a rule for adjusting.

Somatropin is one of the few compounds in this reference quoted in two incompatible unit systems. Older material and much of the grey market use international units (IU); modern labeling uses milligrams. The conversion in general use is roughly 3 IU per mg, so a figure that looks small in one system looks large in the other.

This is not a trivia point. Someone converting in the wrong direction is off by a factor of nine, and the direction of that error is not self-evident from the number alone. Approved products sidestep the issue by shipping pre-measured pens and cartridges whose delivered amount is defined by the device; reconstituted vials of unlabeled material do not.

The clinical goal in approved use is restoring IGF-1 to an age-appropriate physiologic range, not maximising it. The evidence supports that framing from both ends. In diagnosed adult deficiency, higher doses moved body composition further — lean mass and fat mass changes were dose-related — but produced no additional lipid benefit over lower doses (PMID 24810900). In people without a deficiency, randomized trials found the same lean-mass shift alongside significantly more edema, arthralgia, carpal tunnel syndrome, and gynecomastia, with no gain in strength or exercise capacity (PMID 17227934, PMID 18347346). More exposure buys adverse events faster than it buys anything else.

Every element that makes labeled dosing work is a monitoring step rather than a number: a documented diagnosis, IGF-1 assays guiding adjustment, periodic glucose checks because the label requires them in all patients, thyroid and cortisol surveillance, and screening against contraindications such as active malignancy. Strip those away and what remains is the pharmacology without any of its controls. That is the reason the responsible framing for somatropin dosing is clinician-directed rather than a figure to copy.